Drug Search Results
More Filters [+]

CMN-005

Alternative Names: CMN-005, CMN005
Latest Update: 2023-03-28
Latest Update Note: Clinical Trial Update

Product Description

CARCIK-CD19. (Sourced from: https://www.coimmune.com/cmn-005/)

Mechanisms of Action: CAR-T,CD19

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CoImmune
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CMN-005

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title